Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teng Jin Ong

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
BMJ (Clinical Research Ed.)|June 18, 2002
Nutritional genomicsRuan Elliott, Teng Jin Ong
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|October 18, 2003
Comparative assessment of gastrointestinal irritant potency in man of tin(II) chloride and tin migrated from packagingPeter J Boogaard, Michel Boisset, Steve Blunden, et al.
Clinical Lung Cancer|June 16, 2018
Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/CarboplatinVera Hirsh, Yin Wan, Fang-Ju Lin, et al.
Drug Design, Development and Therapy|June 7, 2018
nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trialCesare Gridelli, Tianlei Chen, Amy Ko, et al.
Cancer|April 2, 2019
Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapyDaniel Morgensztern, Amy Ko, Mary O'Brien, et al.
Frontiers in Oncology|December 19, 2019
Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With <i>nab</i>-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung CancerJonathan W Goldman, David M Waterhouse, Ben George, et al.
Frontiers in Oncology|February 12, 2021
<i>nab</i>-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled AnalysisCorey J Langer, Ajeet Gajra, Cesare Gridelli, et al.
Frontiers in Oncology|August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2Ajeet Gajra, Nagla Abdel Karim, Deborah A Mulford, et al.
Frontiers in Oncology|March 1, 2021
<i>nab</i>-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, et al.
Future Oncology (London, England)|April 2, 2020
Quality of life with second or third line <i>nab</i>-paclitaxel-based regimens in advanced non-small-cell lung cancerSantiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
BMJ (Clinical Research Ed.)|June 18, 2002
Nutritional genomicsRuan Elliott, Teng Jin Ong
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|October 18, 2003
Comparative assessment of gastrointestinal irritant potency in man of tin(II) chloride and tin migrated from packagingPeter J Boogaard, Michel Boisset, Steve Blunden, et al.
Clinical Lung Cancer|June 16, 2018
Quality-adjusted Outcomes Stratified by Response in Patients With Advanced Non-Small-cell Lung Cancer Receiving First-line nab-Paclitaxel/Carboplatin or Paclitaxel/CarboplatinVera Hirsh, Yin Wan, Fang-Ju Lin, et al.
Drug Design, Development and Therapy|June 7, 2018
nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trialCesare Gridelli, Tianlei Chen, Amy Ko, et al.
Cancer|April 2, 2019
Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapyDaniel Morgensztern, Amy Ko, Mary O'Brien, et al.
Frontiers in Oncology|December 19, 2019
Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With <i>nab</i>-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung CancerJonathan W Goldman, David M Waterhouse, Ben George, et al.
Frontiers in Oncology|February 12, 2021
<i>nab</i>-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled AnalysisCorey J Langer, Ajeet Gajra, Cesare Gridelli, et al.
Frontiers in Oncology|August 9, 2018
<i>nab</i>-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2Ajeet Gajra, Nagla Abdel Karim, Deborah A Mulford, et al.
Frontiers in Oncology|March 1, 2021
<i>nab</i>-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, et al.
Future Oncology (London, England)|April 2, 2020
Quality of life with second or third line <i>nab</i>-paclitaxel-based regimens in advanced non-small-cell lung cancerSantiago Ponce Aix, Denis Talbot, Ramaswamy Govindan, et al.
Pageof 2